Andrew Protheroe

15.0k citations

124 papers · 6.0k indexed · 2 hit papers · h-index 34

Impact in

Pulmonary and Respiratory Medicine top 0.5%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
Cancer Research top 1%
- Cancer, Lipids, and Metabolism

Papers in

Pulmonary and Respiratory Medicine 73
- Renal cell carcinoma treatment 32
- Prostate Cancer Treatment and Research 30
Cancer Research 26
- Cancer Genomics and Diagnostics 12

Co-authors: Karim Fizazi Nobuaki Matsubara A. Rodrı́guez-Antolı́n Kim N.Valentine M. Macaulay Luis Fein Susan Feyerabend B. Yа. Alekseev
Journals: Journal of Clinical Oncology (25 papers)British Journal of Cancer (9 papers)Annals of Oncology (8 papers)British Journal of Urology (6 papers)Clinical Cancer Research (5 papers)
Partner nations: United Kingdom United States France

In The Last Decade

Andrew Protheroe

115 papers receiving 5.9k citations

Hit Papers

align trajectories log scale

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial 2019 · 517 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2019 The Lancet Oncology
2017 New England Journal of Medicine

Peers

Countries citing papers authored by Andrew Protheroe

Since Specialization

Citations

This map shows the geographic impact of Andrew Protheroe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Protheroe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Protheroe more than expected).

Fields of papers citing papers by Andrew Protheroe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Protheroe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Protheroe. The network helps show where Andrew Protheroe may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Andrew Protheroe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew Protheroe Line = papers co-authored together Andrew Protheroe links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Real world, multicentre patterns of treatment and survival in metastatic renal cell carcinoma with the UK Renal Oncology Collaborative (UK ROC): Is it time to look favourably on first‐line immunotherapy containing combinations in all IMDC groups? Cancer Medicine ·John McGrane, 英俊大西, Amarnath Challapalli, Jean Ph, A M Vdovina, Alison Clayton, زينب محمد حسن, Anand Sharma, Marwa O. Elgendy, Natalie Charnley, Wael Mohamed, Sarah Kingdon, Andrew Protheroe, Anna Lydon, Minghua Liu WENZHEN, Liru Meshak, Iqtedar A Muazzam, Dawn Lee, G. J. Meléndez‐Torres, Amit Bahl	2024	0
2	Genomic Evolution and Transcriptional Changes in the Evolution of Prostate Cancer into Neuroendocrine and Ductal Carcinoma Types International Journal of Molecular Sciences ·Srinivasa R. Rao, Andrew Protheroe, Lucia Cerundolo, David Maldonado‐Pérez, Lisa Browning, Alastair Lamb, Richard J. Bryant, Ian G. Mills, Dan J. Woodcock, Freddie C. Hamdy, Ian Tomlinson, Clare Verrill	2023	0
3	PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non‐muscle‐invasive bladder cancer SHILAP Revista de lepidopterología ·Victoria K. Woodcock, Ji‐Li Chen, Karin Purshouse, Geidi Rodríguez, Linda Collins, M. Gayalin, C. Earl Morrow, Sara Zamora‐Terol, Corran Roberts, Andrea Tarlton, Margarida Rei, Giorgio Napolitani, Mariolina Salio, Mark R. Middleton, Vincenzo Cerundolo, Jeremy Crew, Andrew Protheroe	2023	6
4	The Use of Digital Pathology and Artificial Intelligence in Histopathological Diagnostic Assessment of Prostate Cancer: A Survey of Prostate Cancer UK Supporters Diagnostics ·Nichapat Rattanapan, Richard Colling, Lisa Browning, Ruddy Manuela Rodriguez Rodriguez, Margaret R. Horton, Andrew Protheroe, Alastair Lamb, Richard J. Bryant, 邵义松, Brian Schuermann, Falguni Aggarwal, Clare Verrill	2022	7
5	Angiokines Associated with Targeted Therapy Outcomes in Patients with Non–Clear Cell Renal Cell Carcinoma Clinical Cancer Research ·Andrew J. Armstrong, Andrew B. Nixon, Grasielle dos Santos Mendonça, Qian Yang, Tim Eisen, Walter M. Stadler, Robert J. Jones, Jorge A. García, Ulka N. Vaishampayan, Joel Picus, Robert E. Hawkins, John D. Hainsworth, Christian Kollmannsberger, Theodore F. Logan, Igor Puzanov, Lisa Pickering, Christopher W. Ryan, Andrew Protheroe, Daniel J. George, Susan Halabi	2021	18
6	680P Cabozantinib and axitinib after VEGF therapy in patients with aRCC: A retrospective cohort study Annals of Oncology ·Janet E. Brown, B. Harrow, 会军丁, Christine McCarthy, Ahmed Ezzat Abd El-Aziz, Andrew Protheroe	2021	1
7	Active surveillance of small renal masses in an older population offers long-term oncological efficacy equivalent to partial or radical nephrectomy European Urology Open Science ·M.E. Sullivan, Nishant Patel, Susan H. Brown, Christopher Blick, Aaron Leiblich, Andrew Protheroe, David Cranston, Richard J. Bryant	2020	1
8	199O A phase II study investigating neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer: Final analysis Annals of Oncology ·Bernadett Szabados, Alejo Rodríguez‐Vida, Ignacio Durán, Simon J. Crabb, Michiel S. van der Heijden, Albert Font Pous, Gwénaëlle Gravis, Kelly Griendling, Andrew Protheroe, Alain Ravaud, Denis Maillet, María José Méndez, Cristina Suárez, Mark Linch, Aaron Prendergast, Charlotte Tyson, Kelly Mousa, Daniel Castellano, Thomas Powles	2020	3
9	682P Results from ADVANCE: A phase I/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 (VTP-800) vaccine in combination with PD-1 checkpoint blockade in metastatic prostate cancer Annals of Oncology ·Mark Tuthill, Federica Cappuccini, RYUUJI MASTUNAGA, Emily Pollock, Ian Poulton, Clare Verrill, Tom Evans, Silke Gillessen, Gerhardt Attard, Andrew Protheroe, Freddie C. Hamdy, Adrian V. S. Hill, Irina Redchenko	2020	4
10	Deep learning for detecting tumour-infiltrating lymphocytes in testicular germ cell tumours Journal of Clinical Pathology ·Nina Linder, Jenny C. Taylor, Richard Colling, 武雅璐, Edward Alveyn, Johnson Joseph, Andrew Protheroe, Mikael Lundin, Johan Lundin, Clare Verrill	2018	53
11	Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) with Haematuria in the Absence of an Upper Urinary Tract Pathology CardioVascular and Interventional Radiology ·Charles R. Tapping, Andrew Macdonald, I. Howard Marshall, Beril DEDEOĞLU, Jeremy Crew, Andrew Protheroe, Mark W. Little, Phil Boardman	2018	19
12	Changing Practice Evaluation—Stage 1 Seminoma: Outcomes With Adjuvant Treatment Versus Surveillance: Risk Factors for Recurrence and Optimizing Follow-up Protocols—Experience From a Supraregional Center Clinical Genitourinary Cancer ·Helen E.J. Tyrrell, David N. Church, Johnson Joseph, Zoë Traill, Mark Sullivan, Mark Tuthill, Clare Verrill, Elias Pintus, Bruna Carolina de Araujo, P. Rogers, Т. О. Андреєва, Andrew Protheroe	2017	7
13	Value of Supraregional Multidisciplinary Review for the Contemporary Management of Testicular Tumors Clinical Genitourinary Cancer ·Karin Purshouse, Robert Watson, David N. Church, Baiwei Mao, Ketki Joshi, Zoë Traill, Mark Sullivan, Ian Roberts, Lisa Browning, Gareth D. H. Turner, Cumberland Mc, Johnson Joseph, Meenali Chitnis, Andrew Protheroe, Clare Verrill	2016	22
14	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial The Lancet Oncology ·Andrew J. Armstrong, Susan Halabi, Tim Eisen, Samuel Broderick, Walter M. Stadler, Robert J. Jones, Jorge A. García, Ulka N. Vaishampayan, Joel Picus, Robert E. Hawkins, John D. Hainsworth, Christian Kollmannsberger, Theodore F. Logan, Igor Puzanov, Lisa Pickering, Christopher W. Ryan, Andrew Protheroe, Christine M. Lusk, O Claesson, Daniel J. George	2016	311
15	CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primary CC-RCC Carcinogenesis ·Swethajit Biswas, Philip J.S. Charlesworth, Gareth D. H. Turner, Russell Leek, S. Korn, Leticia Campo, Helen Turley, Sven Sahlin, Andrew Protheroe, David Cranston, Kevin C. Gatter, Francesco Pezzella, Adrian L. Harris	2012	46
16	Type 1 Insulin-like Growth Factor Receptor Translocates to the Nucleus of Human Tumor Cells Cancer Research ·Tamara Aleksic, Meenali Chitnis, Olga V. Perestenko, Shan Gao, Peter H. Thomas, Gareth D. H. Turner, Andrew Protheroe, Mark Howarth, Valentine M. Macaulay	2010	169
17	Cisplatin-associated thrombosis Anti-Cancer Drugs ·Mariam Jafri, Andrew Protheroe	2008	55
18	Phase I study of ispinesib (SB-715992) in combination with docetaxel in patients with advanced solid tumors. Clinical Cancer Research ·Sarah P. Blagden, M. Vališ M, R. Molife, Miranda Payne, Alison Reid, Andrew Protheroe, Steven J. Kathman, Dallas Williams, Carolyn J. Bowen, Jeffrey P. Hodge, Magano Mutepua, Johann S. de Bono, Mark R. Middleton	2005	1
19	Preliminary experience using high-intensity focused ultrasound for the treatment of kidney and liver tumours British Journal of Cancer ·Ally Koh, James E. Kennedy, Feng Wu, Gail ter Haar, Rachel R. Phillips, Andrew Protheroe, Mark R. Middleton, David Cranston	2004	1
20	Urinary concentrations of the soluble adhesion molecule E-cadherin and total protein in patients with bladder cancer British Journal of Cancer ·Andrew Protheroe, Rosamonde E. Banks, Nana Mtambo, Quevedo-Fernandez Enrique, Jennifer Southgate, Priya Singh, Virginie Limousin, Patricia Harnden, Philip H. Smith, Peter Whelan, Peter J. Selby	1999	30

About Andrew Protheroe

Andrew Protheroe is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Surgery and Radiology, Nuclear Medicine and Imaging, having authored 124 papers that have together received 6.0k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (32 papers), Prostate Cancer Treatment and Research (30 papers), Bladder and Urothelial Cancer Treatments (22 papers), Renal and related cancers (19 papers), Cancer Immunotherapy and Biomarkers (17 papers), Radiopharmaceutical Chemistry and Applications (13 papers), Urinary and Genital Oncology Studies (13 papers) and Cancer Genomics and Diagnostics (12 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (3.3k citations), Cancer Research (1.4k citations), Radiology, Nuclear Medicine and Imaging (1.2k citations), Endocrinology, Diabetes and Metabolism (865 citations) and Oncology (1.4k citations). Andrew Protheroe has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Karim Fizazi, Nobuaki Matsubara, A. Rodrı́guez-Antolı́n, Kim N., Valentine M. Macaulay, Luis Fein, Susan Feyerabend, B. Yа. Alekseev, Mustafa Özgüroğlu and Dingwei Ye. Their work appears in journals such as Journal of Clinical Oncology, British Journal of Cancer, Annals of Oncology, British Journal of Urology and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact